Publications
Chung, J. F. et al. NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget (2016).
Chung, J. F., Lee, S. J. & Sood, A. K. Immunological and pleiotropic effects of individual beta-blockers and their relevance in cancer therapies. Expert opinion on investigational drugs (2016).
Chung, J. F., Lee, S. J. & Sood, A. K. Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget (2017).
Lee, S. J., Park, S. H., Chung, J. F., Choi, W. & Huh, H. K. Homocysteine-induced peripheral microcirculation dysfunction in zebrafish and its attenuation by L-arginine. Oncotarget (2017)
Chung, J. F., Her, Z., Kong, W. M. & Chen, Q. Parthanatos-inducing zinc agent C010DS-Zn elicits anti-tumor immune responses involving T cells and macrophages in vivo. Pharmacovigilance and Drug Safety (2021).
Chung, J. F. Chemo 2.0: Programmed necrosis agents for broader and more effective cancer immunotherapy. Annals of Biological Research (2021).
Chung, J. F. Future oncology concerns from post-COVID19 macrophage abberations. EC Pharmacology and Toxicology (2021).
Chung, J. F. COVID19 Vaccine's Delta Paradox and Dangers of Further Viral Evolution. EC Pharmacology and Toxicology (2021).
Chung, J. F. Long COVID, Non-COVID19 Excess Deaths, and Post-Pandemic Cardiovascular Disease Risks: Mechanistic Links and Intervention Opportunities. Medical Research Archives (2023).
Presentations
Chung, J. F. COVID19 briefs for DB Schenker: Importance of prevention and hygiene practices DB Schenker COVID19 Response Conference (24 Apr 2020).
Chung, J. F. Fast tracking C010DS Zn: PARP1 agonist targeting cancer and M2 like macrophages Translational Oncology Summit (24 Sep 2020).
Chung, J. F. Future landscape on post-COVID19 oncology product development. A Conference on Complex Pharmaceuticals Manufacturing Technology (16 Nov 2021).